News / Health

GSK Cancer Vaccine Fails Again, Testing Continues

FILE - The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai.
FILE - The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai.
Reuters
An experimental cancer vaccine from GlaxoSmithKline has failed in a second test - this time against lung cancer - but the British company said it still hoped to identify a sub-group of patients on which it would work.
 
Thursday's news that the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in a late-stage study is a further blow to the high-risk, high-reward project after a similar setback in melanoma in September.
 
Unlike traditional preventative vaccines, the MAGE-A3 treatment is designed for people with established disease, helping their immune systems to prevent the return of disease after surgery.
 
The large Phase III study, involving more than 2,000 lung cancer patients, found that the experimental therapy did not help patients live longer without their disease recurring.
 
Nonetheless, GSK plans to continue the clinical trial in the hope of finding a sub-population that will benefit. It is also doing the same with patients suffering from melanoma and results of analyzes looking at these sub-sets of patients with particular genetic profiles are expected in 2015.
 
Vincent Brichard, head of immunotherapeutics at GSK Vaccines, said the company was disappointed by the outcome but remained committed to the project.
 
Shares in GSK fell by 2 percent by 0945 GMT, underperforming a 0.7 percent decline in the European drugs sector.
 
Many investors had been expecting a disappointing read-out from the lung cancer study, following the earlier setback in melanoma, and there are doubts as to whether GSK will be able to prove the vaccine works for a smaller group of genetically selected patients.
 
But despite the problems GSK Chief Executive Andrew Witty painted a surprisingly upbeat picture of prospects for MAGE-A3 at full-year results last month. Witty described the cancer vaccine and another drug for heart disease called darapladib that has also disappointed in tests as among the most promising in the company's pipeline.
 
10 percent chance
 
Citi analyst Andrew Baum said he estimated there was a 10 percent probability that MAGE-A3 could result in a significant benefit in a gene-signature defined population group, which would still be a substantial market.
 
As a result, Citi has a risk-adjusted sales forecast for the product of 216 million pounds ($360 million) in 2022.
 
Other companies, including Bristol-Myers Squibb, Roche and Merck & Co, have had some recent notable successes in clinical trials of innovative drugs to boost the immune system, but GSK is still pushing the scientific boundaries with its vaccine-based approach.
 
So-called immunotherapy, in which the body's own immune system is enlisted to fight tumor cells, is a hot area of pharmaceutical research and development at the moment, although cancer vaccines have proved difficult to develop over the years.
 
U.S.-based Agenus has contributed technology to the GSK vaccine and its shares are sensitive to news on the project. The vaccine contains Agenus' QS-21 Stimulon adjuvant, or booster.
 
Although news on MAGE-A3 and darapladib has been disappointing for GSK, the company's overall drug research has been improving recently, with notable new drug approvals in 2013 for HIV, cancer and respiratory disease.
 
GSK, which is the only major drugmaker to report its internal rate of return on R&D investment, said last month that returns had now reached 13 percent, up from 12 percent two years earlier and 11 percent in 2010. It has set a target of reaching 14 percent.

You May Like

Is Air Travel Safe?

Aviation expert says despite tragic losses of Malaysian Airlines flights 370 and 17, industry experienced lowest fatality rate in recorded history last year More

Multimedia 100 Days Later, Nigerian Girls Still Held

Activists holding rallies in Nigeria and several other countries to mark 100th day of captivity for more than 200 schoolgirls being held by Boko Haram More

Chocolate Too Bitter? Swap Sugar for Mushrooms

US food technology company develops fermentation process using mushrooms to reduce bitterness in cocoa beans, believes it will cut sugar content in candy More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
US Carriers Suspend Travel to Israeli
X
Carolyn Presutti
July 23, 2014 1:21 AM
The United States is prohibiting American carriers from flying to Israel's airport in Tel Aviv for 24 hours, because of rising violence between Israel and Hamas militants. The action was announced on Tuesday, after a rocket fired by Hamas militants in the Gaza Strip landed near the airport. As VOA's Carolyn Presutti tells us, international officials soon may have to determine which combat zones are too dangerous for commercial flights.
Video

Video US Carriers Suspend Travel to Israel

The United States is prohibiting American carriers from flying to Israel's airport in Tel Aviv for 24 hours, because of rising violence between Israel and Hamas militants. The action was announced on Tuesday, after a rocket fired by Hamas militants in the Gaza Strip landed near the airport. As VOA's Carolyn Presutti tells us, international officials soon may have to determine which combat zones are too dangerous for commercial flights.
Video

Video NASA Focuses on Earth-Like Planets

For decades, looking for life elsewhere in the universe meant listening for signals that could be from distant civilizations. But recent breakthroughs in space technology refocused some of that effort toward finding planets that may harbor life, even in its primitive form. VOA’s George Putic reports on a recent panel discussion at NASA’s headquarters, in Washington.
Video

Video IAEA: Iran Turns its Enriched Uranium Into Less Harmful Form

Iran has converted its stockpiles of enriched uranium into a less dangerous form that is more difficult to use for nuclear weapons, according to the United Nations’ Atomic Energy Agency. The move complies with an interim deal reached with Western powers on Iran's nuclear program last year, in exchange for easing of sanctions. Henry Ridgwell reports for VOA from London.
Video

Video Relic of Saint Draws Catholics Worried About Immigration Issue

A Roman Catholic saint who is a figure of devotion for those crossing the border into the United States is attracting believers concerned about the plight of undocumented immigrants. Mike O'Sullivan reports from Los Angeles, where a relic of Saint Toribio has drawn thousands to local churches.
Video

Video US Awards Medal of Honor for Heroics in Bloodiest of Afghan Battles

U.S. combat troops are withdrawing from Afghanistan, on pace to leave the country by the end of this year. But on Monday, U.S. President Barack Obama took time to honor a soldier whose actions while under fire in Afghanistan earned him the Medal of Honor. VOA's Jeff Seldin has more from the Pentagon.
Video

Video Ukraine Rebels Surrender MH17 Black Boxes

After days of negotiations, a senior separatist leader handed over two black boxes from an airliner downed over eastern Ukraine to Malaysian experts early Tuesday. While on Monday, the U.N. Security Council unanimously demanded that armed groups controlling the crash site allow safe and unrestricted access to the wreckage.
Video

Video In Cambodia, HIV Diagnosis Brings Deadly Shame

Although HIV/AIDS is now a treatable condition, a positive diagnosis is still a life altering experience. In Cambodia, people living with HIV are often disowned by friends, family and the community. This humiliation can be unbearable. We bring you one Cambodian woman’s struggle to overcome a life tragedy and her own HIV positive diagnosis.
Video

Video Nature of Space Exploration Enters New Age

Forty-five years ago this month, the first humans walked on the moon. It was during an era of the space race between the United States and the Soviet Union. World politics have changed since then and -- as Elizabeth Lee reports -- so has the nature of space exploration.

AppleAndroid